In patients with breast cancer, HER2 was detected in 39% (65/168), FGFR1 was detected in 32% (19/60), ER was detected in 26% (44/168), and PR was detected in 4% (5/120) (Table 5). Here, ERBB2 is linked to breast carcinoma.